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Abstract 
 
The rapid identification and differentiation of members of the Mycobacterium 
tuberculosis complex (MTBC) is essential to assess the potential zoonotic risk. Different 
available molecular methods are time consuming since they depend on cultivation of 
mycobacteria. High Resolution Melting (HRM) is a low cost, rapid and easy to perform 
single-tube method not limited to cultured samples. In this study, a HRM assay specifically 
targeting gyrB was developed to simultaneously identify and differentiate Mycobacterium 
(M.) tuberculosis, M. microti and M. bovis/M. caprae. To evaluate the performance of this 
assay, 38 MTBC isolates and 25 directly extracted clinical specimens were analysed. HRM 
results of all 38 (100%) examined isolates correlated with the results obtained with the 
commercially available GenoType MTBC test (Hain Lifescience). From the 25 clinical 
specimens tested, species identification by HRM showed concordant results with the 
previously used identification methods in 23 samples (92%). The assay demonstrated a good 
analytical sensitivity, specificity and reproducibility and can be used directly on clinical 
specimens. 
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Zusammenfassung 
 
Die schnelle Identifizierung und Differenzierung von Mitgliedern des Mycobacterium- 
tuberculosis-Komplexes (MTBC) ist essentiell, um das mögliche zoonotische Risiko zu 
beurteilen. Verschiedene verfügbare molekulare Methoden sind zeitaufwendig, da sie von der 
Kultivierung der Mykobakterien abhängen. High Resolution Melting (HRM) ist eine 
kostengünstige, schnelle und einfach durchzuführende Methode, die nicht auf kultivierte 
Proben beschränkt ist. In dieser Studie wurde ein HRM-Test entwickelt, welcher auf dem 
Zielgen gyrB basiert, um gleichzeitig Mycobacterium (M.) tuberculosis, M. microti und M. 
bovis/M. caprae zu identifizieren und zu differenzieren. Um diesen Test zu validieren, wurden 
38 MTBC-Isolate und 25 direkt extrahierte klinische Proben analysiert. Die HRM-Ergebnisse 
aller 38 (100%) untersuchten Isolate korrelierten mit den Ergebnissen des kommerziell 
erhältlichen GenoType MTBC-Tests (Hain Lifescience). Von den 25 getesteten klinischen 
Proben war die Identifikation der MTBC Spezies durch HRM in 23 Proben (92%) 
übereinstimmend mit den zuvor verwendeten Identifikationsmethoden. Der Test zeigte eine 
gute analytische Sensitivität, Spezifität und Reproduzierbarkeit und kann direkt für klinische 
Proben verwendet werden. 
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Introduction 
 
Mycobacterium tuberculosis complex (MTBC) consists of the closely related species 
Mycobacterium (M.) tuberculosis, M. bovis, M. bovis Bacillus Calmette and Guérin (BCG), 
M. caprae, M. africanum, M. microti, M. pinnipedii, M. canettii and three further species (M. 
orygis, the dassie bacillus, M. mungi)1. M. tuberculosis and M. africanum are often described 
as host-specific to humans. According to the recent WHO report from 2017, tuberculosis is 
still the leading cause of human death from a single infectious agent with 6.3 million new 
cases and an estimated 1.7 million deaths in 20162. Additionally, several cases of M. 
tuberculosis infections in animals have been reported3–5. Bovine tuberculosis (bTB) is an 
important zoonosis most commonly caused by M. bovis and less frequently by M. caprae1. 
New cases of bTB in 2013 in Switzerland6, resulting in the implementation of a national bTB 
surveillance program, highlighted the importance of routine species-level identification. This 
program consists of a systematic microbiological testing of suspicious lymph nodes found 
linked to meat inspection in slaughterhouses. Fast and reliable identification and 
differentiation between the species within this MTB complex is important to assess the 
potential zoonotic risk and is therefore a fundamental procedure for public health surveillance 
and food safety. 
Identification of MTBC is based on different PCR based methods targeting 16S rRNA or 
IS61107,8. In contrast, differentiation of Mycobacterium species within the MTBC is more 
laborious. Diverse molecular methods such as the GenoType MTBC test (Hain Lifescience, 
Nehren, Germany) or restriction fragment length polymorphism9,10 are used although having 
limitations in the reliance on bacterial cultures to produce a valid amount of bacterial DNA. 
Mycobacteria especially M. microti requires several months to obtain significant growth 
underlining a delayed time span to get valid results of MTBC species-level identification. 
Spoligotyping uses polymorphism on the direct repeat locus for differentiation and typing of 
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MTBC11. A result is obtained in one or two days comprising several working steps such as 
PCR, membrane preparation, hybridisation, washing steps and detection by 
chemiluminescence. On the other hand, newer alternatives to conventional spoligotyping such 
as Luminex technology or Spoligotyping by MALDI-TOF MS requires advanced and 
expensive equipment12. Numerous single-tube multiplex RT-PCR assays have been 
previously proposed for MTBC species discrimination, mainly targeting several region of 
differences (RD)13–17. The complexity of a multiplex RT-PCR reaction can be a problem for 
intricate veterinary samples often dealing with animal tissues.  
High resolution melting (HRM) assay is reported as a rapid and low cost assay to detect 
single-nucleotide polymorphism (SNP)18. The assay characterizes amplified PCR products 
according to their dissociation behaviour without requiring additional instrumentation. A 
fluorescently labelled dye binding to double stranded DNA is combined with amplicons 
resulting from the PCR reaction. When increasing the temperature, the double stranded DNA 
dissociates into single strands leading to a decrease in fluorescence intensity. The melting 
temperature depends on GC content, length and nucleotide sequence. It is an easy to perform 
and single-tube method leading to a result within approximately two hours. Moreover, HRM 
is not limited to cultured material but is able to detect DNA in clinical specimens directly 
extracted from tissue samples. Various HRM assays are already used successfully to identify 
and differentiate many bacteria species such as Mycoplasma synoviae19, Chlamydiaceae sp.20, 
Staphylococcus aureus21, Brucella sp.22 and Leptospira sp.23. Among Mycobacteria sp. HRM 
is a tool often reported to analyse drug resistance in M. tuberculosis24–26. Furthermore, the 
method is used to differentiate non-tuberculous mycobacteria (NTM) and to distinguish them 
from MTBC27–29. Wright et al. designed a HRM assay to detect the Region of Deletion 9 
(RD9) with the aim of differentiating M. tuberculosis from other members of MTBC in fine-
  9 
needle aspiration biopsies30. However, the drawback of this study lies in its poor sensitivity of 
only 51.9%. Other studies combined RD-targeted multiplex RT-PCR assays with HRM14,17. 
In this study, a novel HRM method based on SNPs located in gyrB was developed to 
simultaneously identify and differentiate members of MTBC to its species-level.  
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Results 
 
HRM analysis with cultured samples 
All cultured samples tested were amplified and resulted in a corresponding melting curve. The 
HRM species-specific melting temperatures Tm (Table 1, Supplementary Table S1) and the 
corresponding melting curves (Fig.1a) of the sample-subset used for determination of the 
intra- and inter-assay reproducibility are shown. Since the Tm ranges are very close to each 
other, it is difficult to clearly distinguish between members of MTBC. On the other hand, the 
difference plot (Fig. 1c) as well as the normalized plot (Fig. 1b) allowed a clear species 
differentiation into the three groups of M. tuberculosis/M. africanum, M. microti and M. 
bovis/M. caprae. The intra-assay coefficiences of variation (CVs) and the inter-assay CVs 
showed values ranging between 0.01 - 0.02% and 0.02 - 0.03%, respectively (Table 1, 
Supplementary Table S1). Species identification results of all 38 (100%) tested cultured 
samples correlated with the GenoType MTBC test (Hain Lifescience) results.   
 
HRM analysis with clinical specimens 
25 clinical specimens were tested in the HRM assay and resulted in three main groups 
consistent with the expected MTBC species. The obtained normalized and difference plots of 
the tested subset of clinical specimens showed a clear discrimination (Fig. 2b/2c). The intra-
assay CVs (Table 2, Supplementary Table S2) were between 0.01 - 0.02% for M. tuberculosis 
and M. caprae, 0.01% for M. bovis and 0.05% for M. microti. The inter-assay CVs (Table 2, 
Supplementary Table S2) were higher than in the cultured samples with values between 0.12 - 
0.15%. From those 25 clinical specimens 23 (92%) showed concordant identification results. 
Two samples revealed lower Tm values at approximately 84 °C, compared to the other sample 
results. The corresponding culture of one of those two clinical specimens (sample 17-2287) 
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showed a correct species identification by HRM. The second clinical specimen (sample 17-
1063) is not successfully cultured yet and further investigations are still ongoing. 
 
Analytical specificity 
In the exclusivity run the tested 41 NTMs and Nocardia paucivorans, Escherichia coli and 
Streptococcus suis either showed no melting curves or melting curves with completely 
different Tm values compared to those obtained from samples of the MTBC. Therefore, the 
assay showed an analytical specificity of 100%. 
 
Limit of detection 
The limit of detection (LOD) for the lowest dilution of which the acceptance criteria were 
fulfilled was 10 genome equivalents (GE) for M. tuberculosis, M. bovis/M. caprae and M. 
microti (Table 3).  
 
Efficiency  
The efficiencies of the RT-PCR were 87% for M. microti, 94% for M. bovis and 85% for 
H37Rv (Supplementary Fig. S1). 
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Discussion 
 
This study reports the development of a HRM assay to identify and distinguish the main 
members of the MTBC complex of clinical specimens and cultured samples in approximately 
two hours. M. microti, M. tuberculosis/M. africanum and M. bovis/M. caprae can be clearly 
and reliably distinguished from each other by unique difference plots. The Tm alone is not 
sufficient to discriminate the main species because of partially overlapping Tm values (Table 1 
and 2). However, after appropriate transformation of the melting curves into normalized and 
difference plots by applying algorithms of the Rotor-Gene Q Software 2.3.1 (Qiagen Hilden, 
Germany), the members of the MTBC can be clearly distinguished into three groups (Fig. 1c 
and 2c). Using this strategy, the species-specific melting profiles showed an unambiguous 
picture. 
To date, MTBC species identification is often based on methods requiring cultured samples10 
or based on time-consuming procedures11. Halse et al. reported the development of a 
multiplex RT-PCR method for clinical specimens, however, this assay is more expensive due 
to the need of five different probes16. Furthermore, the complexity of such a multiplex 
reaction can be challenging when analysing tissue samples comprising various substances 
containing large amounts of co-extracted host DNA and ingredients, which can lead to 
inhibition of the PCR reaction31. Other studies evaluated mainly cultured isolates13–15,17. The 
main advantage of our developed HRM assay compared to previous studies is the 
implementation of a relatively cheap and straightforward singleplex method for directly 
extracted clinical specimen. 
The current HRM assay identified MTBC positive cultured samples in complete agreement 
with results of the GenoType MTBC test (Hain Lifescience). The clinical specimens showed a 
concordance of 92%. The remaining 8% (n=2) showed unspecific melting curves not allowing 
  13 
to assign the samples to MTBC using the developed method. Both samples derived from 
alpaca tissues, either from spleen or from a mix of different tissues including lymph node, 
lung, heart, liver and cervical vertebra. All 23 clinical samples lead to an unambiguous and 
correct result derived from lymph nodes, lung or liver tissues (Supplementary Table S3). It is 
likely that the content of these particular alpaca tissues interfered with the melting procedure. 
Further investigations to clarify this finding are continuing. 
The intra- and inter-assay CVs showed very low values demonstrating a very good 
reproducibility of the method. The analytical specificity displayed a perfect value of 100% 
indicating a MTBC specific assay. Furthermore, the assay demonstrated a good PCR 
efficiency of more than 85% and a good sensitivity with a LOD of 10 GE. 
One limitation of the assay is its inability to distinguish between M. bovis, M. bovis BCG and 
M. caprae with this particular primer set. Moreover, M. africanum cannot be separated from 
M. tuberculosis. In order to design a HRM assay having a high resolution detecting SNPs, the 
PCR amplicon should optimally not exceed 150 bp since longer amplicons would have a 
negative impact on the resolution of the assay. SNPs distantly located within a gene, as in the 
case of gyrB, are impossible to analyse by HRM using just one primer pair. Our primary goal 
was to clearly distinguish M. microti from other members of the MTBC complex since its 
proper identification in directly extracted clinical samples are advantageous considering its 
long cultivation time. Therefore, our developed HRM assay was restricted to the detection of 
2 out of 5 possible SNPs within the gyrB gene10 resulting in a clear and rapid identification 
and differentiation of the three main MTBC species most relevant to veterinarians. In order to 
overcome the described limitation, there is the possibility to extend the HRM assay with a 
second primer pair, resulting in a two-reaction HRM paradigm, targeting a region to further 
discriminate M. bovis from M. caprae and M. africanum subtype I from M. tuberculosis. In 
addition, another drawback of the developed assay seems to lie in the failure of detection of 
  14 
samples deriving from certain alpacas (two out of four tested alpacas), especially samples 
containing spleen or bone. 
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Conclusion 
 
The developed HRM assay enables the simultaneous identification and differentiation of 
MTBC between the three clinically most relevant groups namely M. tuberculosis/M. 
africanum, M. microti and M. bovis/M. caprae from tissue samples as well as from cultured 
material. Therefore, the use of this powerful assay may save several months of cultivation 
time to differentiate between species of MTBC. It is an easy to perform, cheap, sensitive and 
specific assay leading to a result in less than two hours. Since tuberculosis is one of the top 10 
causes of death worldwide, it is expected that a cost-effective and easy to set-up assay could 
be implemented in laboratories with moderate resources as a high-throughput screening and 
confirmatory tool for MTBC infections. This would significantly contribute to develop 
efficient public health and veterinary surveillance strategies worldwide. 
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Materials and methods 
 
Ethics statement 
This study was carried out in accordance with the recommendations of Swiss federal 
regulations (TSV 916.401 and VSFK 817.190). Analysis of animal specimens was carried out 
within an official context of monitoring bovine tuberculosis and NTM infections, meaning 
that no animals were killed for the purposes of this research project and ethical approval was 
not necessary. 
 
Reference strains and samples 
62 MTBC positive samples originating from 40 different animals and tissues (Table 4, 
Supplementary Table S3) were used for assay development. One additional isolate of a wild 
boar was kindly provided by Lucía de Juan Ferré and Beatriz Romero Martinez from the 
European Union Reference Laboratory for Bovine Tuberculosis in Madrid. Finally, a total of 
63 samples comprising 38 isolates and 25 clinical specimens were tested. Reference strains 
M. microti ATCC 19422, M. bovis BCG Pasteur ATCC 35734 and M. tuberculosis H37Rv 
were included as positive controls in each run. To determine the specificity of the optimized 
HRM assay a set of 41 different non-tuberculous mycobacteria (NTM) was additionally tested 
(Supplementary Table S4). Moreover, Nocardia paucivorans, Escherichia coli and 
Streptococcus suis were included in this exclusivity panel in order to test for any non-specific 
signals. 
 
Culture and DNA extraction 
Sample preparation, culture and DNA extraction were proceeded as described previously6. 
Briefly, genomic DNA was extracted harvesting mycobacteria from 1.5 ml of MGIT 
subcultures by centrifugation for 10 min at 13,000 × g. The sediment was suspended in 180 µl 
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ATL buffer (Qiagen), transferred onto a bead beating matrix in a 2 ml microtube (Omni 
International, Kennesaw, USA), heat inactivated and subjected to mechanical cell lysis using 
a TissueLyser II (Qiagen) and enzymatic digestion with Proteinase K (Qiagen). Automated 
DNA preparation was performed on the QIAcube instrument using the QIAamp cador 
Pathogen Mini Kit protocol (Qiagen). DNA concentration was measured using a NanoDrop 
2000c Spectrophotometer (Thermo Fisher Scientific, Reinach, Switzerland) and stored at −20 
°C until use. DNA obtained from pure mycobacterial cultures were identified as MTBC using 
artus M. tuberculosis RG PCR Kit (Qiagen). Species identification of cultured samples was 
performed by GenoType MTBC test (Hain Lifescience). Clinical specimens were tested by 
Spoligotyping32 and multi-locus variable number tandem repeat analysis using an 
internationally established 24-loci panel33. Standard biosecurity procedures have been carried 
out for handling of samples. Cultures involving MTBC or NTM isolates were performed at 
the Biosafety Level 3 facility until heat deactivation. Sample preparation and DNA extraction 
were carried out under Biosafety Level 2 containment. 
 
HRM development and optimisation 
A primer pair was designed specifically targeting a conserved region for MTBC on the gyrB 
gene. The forward HRM_gyrB_for (5’-CGGCTCGAAGTCGAGATCAAG-3’) and reverse 
HRM_gyrB_rev (5’-TTCGAAAACAGCGGGGTCG-3’) primers flank a 144 base pair (bp) 
amplicon. In contrast, other closely and distantly related NTM have a greater variability in the 
primer region as well as in the whole 144 base pair amplicon (Fig. 3). 
The HRM assay was performed on the Rotor-Gene Q system (Qiagen) with the Type-it HRM 
PCR Kit (Qiagen). The reaction was performed in a total volume of 15 µl. 1 µl of sample 
DNA was added to a reaction mixture containing 7.5 µl 2X Type-it HRM Mastermix  
containing EvaGreen DNA-binding dye (Qiagen), 0.5 µM final concentration of each primer 
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(Microsynth AG, Balgach, Switzerland) and ultrapure water. The PCR thermocycling 
conditions were as follows: initial denaturation at 95 °C for 5 min, 40 cycles with 
denaturation at 95 °C for 10 s and annealing/extension at 55 °C for 30 s followed by a second 
cycling step at 95 °C for 10 s and 40 °C for 2 min followed by a HRM ramping from 80 °C to 
93 °C. Fluorescence data were acquired at 0.1 °C increments every 2 s to generate specific 
melting curves. For each experiment, the three reference strains M. microtii ATCC 19422, M. 
bovis BCG Pasteur ATCC 35734 and M. tuberculosis H37Rv were included as melting curve 
standards and positive controls. To exclude contaminations in the reaction mixture, ultrapure 
water was added as a negative control in each experiment. 
Data analysis was performed using Rotor-Gene Q Software 2.3.1 (Qiagen). Normalized and 
difference plots were generated. To normalize the results, the pre-melt (initial fluorescence) 
and post-melt (final fluorescence) signals of all samples were set to uniform relative values 
from 100% to 0%. In order to generate difference plots, normalized fluorescence data of 
sample curves were subtracted from a reference curve of M. bovis BCG Pasteur ATCC 35734 
to visually accentuate differences in a greater resolution. The threshold value for peak calling 
was set at 0.5 dF/dT. 
In order to alleviate false negative results due to inhibition, clinical specimens were tested in 
duplicate undiluted and as a 1:5 dilution. The cultured samples were tested at concentrations 
between 100 pg and 10 ng. 
To examine the intra- and inter-assay CV of the Tm, representing the repeatability of the 
developed HRM method, a randomly chosen subset of 22 cultured and 19 clinical specimens 
were tested in triplicates in three independent runs at three different days. 
 
 
 
  19 
 Analytical Specificity 
In order to proof the analytical specificity of the primers an exclusivity panel including 
NTMs, Nocardia paucivorans, Escherichia coli and Streptococcus suis were tested. 
 
 
Efficiency and limit of detection 
The efficiency and the analytical sensitivity of the RT-PCR were evaluated by triplicate 
testing of a 10-fold serial dilution series of each of the three reference strains. With an 
estimated genome size of 4.4 Mb, a DNA quantity of 4.8 fg was calculated for one GE of 
MTBC. The limit of detection was determined as lowest dilution with amplification of all 
triplicates with a standard deviation of ≤ 0.5. 
 
Data Availability 
Data generated during the study is presented in an analysed format in this manuscript. Raw 
datasets generated from the intra- and inter-assays are included in the Supplementary 
Information file. Additional raw data are available from the corresponding author on 
reasonable request. 
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Table 1: Melting temperatures (mean and standard deviation) of the intra- and inter-assay of a 
randomly chosen subset of cultured samples for different MTBC species with its 
corresponding coefficients of variation (CV) in % are listed.  
 
  Run 1 Run 2 Run 3 Inter-Assay 
  CV% Tm values CV% Tm values CV% Tm values CV% Tm values 
M. tuberculosis H37Rv   86.93   86.98   86.95 
 
  
M. bovis BCG Pasteur 
ATCC 35734   86.60   86.58   86.58    
M. microti ATCC 19422   86.75   86.72   86.73 
 
  
M. tuberculosis (n=3) 0.02 86.99 ± 0.04 0.01 86.98 ± 0.03 0.02 87.00 ± 0.03 0.02 86.99 ± 0.04 
M. caprae (n=6) 0.02 86.57 ± 0.04 0.02 86.58 ± 0.05 0.01 86.62 ± 0.04 0.03 86.59 ± 0.06 
M. bovis (n=6) 0.02 86.58 ± 0.05 0.02 86.60 ± 0.05 0.02 86.64 ± 0.04 0.03 86.60 ± 0.07 
M. microti (n=7) 0.02 86.74 ± 0.07 0.02 86.73 ± 0.05 0.01 86.75 ± 0.05 0.03 86.74 ± 0.07 
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Table 2: Melting temperatures (mean and standard deviation) of the intra- and inter-assay of a 
randomly chosen subset of clinical specimens for different MTBC species with its 
corresponding coefficients of variation (CV) in % are listed. 
 
  Run 1 Run 2 Run 3 Inter-Assay 
  CV% Tm values CV% Tm values CV% Tm values CV% Tm values 
M. tuberculosis H37Rv   86.80   86.93 
 
86.75 
 
  
M. bovis BCG Pasteur 
ATCC 35734   86.38   86.55  86.37    
M. microti ATCC 19422   86.52   86.70 
 
86.48 
 
  
M. tuberculosis (n=2) 0.01 86.73 ± 0.01 0.02 86.91 ± 0.03  0.02 86.70 ± 0.03 0.13 86.80 ± 0.13 
M. caprae (n=5) 0.01 86.27 ± 0.17 0.02 86.45 ± 0.15 0.02 86.34 ± 0.12 0.12 86.35 ± 0.25 
M. bovis (n=6) 0.01 86.41 ± 0.06 0.01 86.59 ± 0.04 0.01 86.36 ± 0.04 0.15 86.48 ± 0.16 
M. microti (n=7) 0.03 86.59 ± 0.04 0.02 86.73 ± 0.05 0.02 86.48 ± 0.05 0.14 86.60 ± 0.17 
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Table 3: Limit of detection of the real-time PCR step within the HRM assay.  Determination 
of Ct values and its standard deviation (SD) of 3 replicates for a dilution series ranging from 1 
to 1'000'000 genome equivalents using the three reference strains M. tuberculosis H37Rv, M. 
bovis Pasteur ATCC 35734 and M. microti ATCC 19422. 
 
MTBC Member Genome 
equivalents Ct SD 
M. tuberculosis H37Rv 1'000'000 16.42 0.10 
  100'000 19.89 0.02 
  10'000 23.76 0.07 
  1000 27.48 0.08 
  100 31.21 0.32 
  10 35.04 0.27 
  1 - - 
M. bovis BCG pasteur ATCC 35734 1'000'000 15.13 0.20 
  100'000 18.61 0.16 
  10'000 22.05 0.16 
  1000 25.75 0.17 
  100 29.38 0.20 
  10 33.15 0.50 
  1 35.51 0.12 
M. microti ATCC 19422 1'000'000 15.73 0.06 
  100'000 19.03 0.05 
  10'000 22.98 0.07 
  1000 26.28 0.13 
  100 30.18 0.17 
  10 33.92 0.14 
  1 37.82 0.73 
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Table 4: MTBC positive samples used for the development of the HRM method. 38 isolates 
obtained from cultured material, whereas 25 samples were clinical specimens directly 
extracted from tissue samples. 62 samples derived from Switzerland whereas one isolate 
originated from Spain.   
 
Species Host  No. of isolates 
cultured material (n=38) 
M. tuberculosis elephant 3 
M. caprae cow 7 
M. bovis  cow 15 
M. microti cat 7 
M. microti alpaca 3 
M. microti llama 2 
M. microti wild boar (Spain) 1 
clinical specimens (n=25) 
M. tuberculosis elephant 2 
M. caprae cow 5 
M. bovis  cow 7 
M. microti cat 5 
M. microti alpaca 4 
M. microti llama 2 
Total 63 
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Figure 1: Representative high resolution melting graphs corresponding to one high resolution 
melting analysis of a subset of cultured samples (n=22). Curves of tested samples previously 
identified as M. tuberculosis are shown in yellow, M. microti in blue, M. bovis/M. bovis BCG 
in red and M. caprae in green. (a) Melting curves; (b) Normalized plot; (c) Difference plot. 
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Figure 2. Representative high resolution melting graphs corresponding to one high resolution 
melting analysis of a subset of clinical specimens (n=19). Curves of tested samples previously 
identified as M. tuberculosis are shown in yellow, M. microti in blue, M. bovis/M. bovis BCG 
in red and M. caprae in green. (a) Melting curves; (b) Normalized plot; (c) Difference plot. 
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Figure 3. Sequence alignment of the amplicon within gyrB generated by the real-time PCR of 
the high resolution melting. Primer regions are indicated in yellow. Red letters and dots 
represent conserved bases whereas blue letters show areas with substitutions. The two single 
nucleotide polymorphisms distinguishing the main members of the Mycobacterium 
tuberculosis complex detected by the high resolution melting assay are highlighted with 
green.  
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Supplementary material 
 
Supplementary Table S1: Raw data set and statistical parameters generated from the intra- 
and inter-assay using a randomly chosen subset of 22 cultured samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
MTBC member sa mple no origin Ct Tm Mean Tm SD CV% Intra-assay CV% Ct Tm Mea n Tm SD CV% Intra-assay CV% Ct Tm Mea n Tm SD CV% Intra-assay CV% Mean Tm SD CV% Inter-assay CV%
M. microti ATCC 19422 23.08 86.75 23.15 86.72 23.38 86.73 86.73 0.02 0.02
M. bovis  BCG Pas teur ATCC 35734 28.46 86.60 28.63 86.58 29.46 86.58 86.59 0.01 0.01
M. tuberculosis H37Rv 25.80 86.93 26.06 86.98 26.36 86.95 86.95 0.03 0.03
M. tuberculosis  15-961 2B elephant 18.47 86.97 86.96 0.01 0.01 18.50 87.00 87.00 0.00 0.00 18.89 86.98 86.98 0.02 0.02 86.98 0.02 0.03
18.49 86.95 18.41 87.00 18.97 86.97
18.47 86.95 18.53 87.00 18.95 87.00
M. tuberculosis  15-1115-2 elephant 20.38 86.95 86.96 0.02 0.02 20.53 87.00 87.00 0.00 0.00 20.78 87.00 87.01 0.01 0.01 86.99 0.03 0.03
19.94 86.98 20.53 87.00 20.65 87.00
20.08 86.95 20.30 87.00 20.60 87.02
M. tuberculosis  15-1221-1 elephant 23.48 86.97 86.99 0.03 0.03 0.02 23.74 86.98 86.97 0.02 0.02 0.01 23.98 86.98 87.00 0.02 0.02 0.02 86.99 0.02 0.02 0.02
23.83 86.97 24.01 86.95 24.20 87.02
23.53 87.02 23.58 86.98 23.85 87.00
M. caprae  14-13 cow 26.57 86.57 86.59 0.02 0.02 27.27 86.55 86.56 0.01 0.01 27.72 86.60 86.61 0.01 0.01 86.59 0.03 0.03
26.82 86.60 27.37 86.57 27.44 86.62
26.52 86.60 27.24 86.55 28.26 86.62
M. caprae 22914 cow 23.99 86.58 86.58 0.00 0.00 24.29 86.57 86.55 0.02 0.02 24.46 86.65 86.64 0.01 0.01 86.59 0.04 0.05
23.87 86.58 24.23 86.53 24.75 86.63
23.97 86.58 24.33 86.55 24.41 86.63
M. caprae 22848 cow 26.57 86.58 86.59 0.01 0.01 26.63 86.57 86.56 0.01 0.01 26.98 86.60 86.60 0.00 0.00 86.58 0.02 0.03
26.73 86.60 26.48 86.55 27.23 86.60
26.55 86.58 26.64 86.55 27.14 86.60
M. caprae 22966 cow 23.75 86.55 86.58 0.03 0.03 23.66 86.60 86.58 0.02 0.02 24.22 86.58 86.59 0.01 0.01 86.58 0.00 0.00
23.00 86.60 23.61 86.58 24.03 86.60
23.44 86.60 23.75 86.57 23.91 86.58
M. caprae  13-450 cow 21.29 86.58 86.58 0.01 0.01 21.39 86.57 86.60 0.03 0.03 21.48 86.58 86.60 0.02 0.02 86.59 0.01 0.01
21.23 86.57 21.35 86.60 21.47 86.60
21.29 86.58 21.31 86.62 21.57 86.62
M. caprae  13-162 cow 25.11 86.58 86.56 0.03 0.03 0.02 25.41 86.63 86.63 0.01 0.01 0.02 25.82 86.58 86.60 0.02 0.02 0.01 86.60 0.03 0.04 0.03
25.17 86.53 25.55 86.63 25.72 86.60
24.82 86.57 25.54 86.62 25.88 86.62
M. bovis 20482 cow 26.55 86.55 86.56 0.01 0.01 26.61 86.62 86.61 0.02 0.03 26.86 86.62 86.63 0.02 0.02 86.60 0.03 0.04
26.39 86.57 26.64 86.62 26.96 86.65
26.31 86.57 26.28 86.58 26.81 86.62
M. bovis 20594 cow 28.22 86.55 86.54 0.01 0.01 28.52 86.60 86.61 0.01 0.01 29.66 86.65 86.65 0.02 0.02 86.60 0.05 0.06
27.85 86.53 28.53 86.62 28.72 86.63
27.40 86.55 28.42 86.60 29.28 86.67
M. bovis 20175 cow 22.06 86.55 86.58 0.03 0.03 21.80 86.58 86.57 0.02 0.02 22.20 86.62 86.64 0.02 0.02 86.60 0.04 0.04
21.30 86.58 21.72 86.58 22.22 86.65
22.02 86.60 21.95 86.55 22.43 86.65
M. bovis 20606 cow 24.19 86.62 86.60 0.02 0.02 24.73 86.60 86.59 0.01 0.01 24.43 86.65 86.65 0.00 0.00 86.61 0.03 0.04
24.30 86.58 24.27 86.58 24.58 86.65
24.23 86.60 24.56 86.60 24.78 86.65
M. bovis 22667 cow 22.92 86.60 86.61 0.01 0.01 22.91 86.60 86.62 0.03 0.03 23.33 86.65 86.64 0.01 0.01 86.62 0.02 0.02
22.87 86.62 23.20 86.65 23.46 86.65
23.06 86.60 23.03 86.60 23.43 86.63
M. bovis 22539 cow 24.09 86.62 86.61 0.01 0.01 0.02 24.39 86.60 86.61 0.02 0.02 0.02 24.79 86.60 86.61 0.02 0.02 0.02 86.61 0.00 0.00 0.03
23.91 86.60 24.59 86.60 24.67 86.63
24.31 86.62 24.24 86.63 25.08 86.60
M. microti 22928 ca t 20.62 86.70 86.73 0.03 0.03 20.57 86.75 86.76 0.01 0.01 20.79 86.73 86.73 0.03 0.03 86.74 0.02 0.02
20.63 86.75 20.76 86.77 20.53 86.70
20.72 86.73 20.86 86.75 20.74 86.75
M. microti  15-1765 ca t 24.74 86.72 86.72 0.02 0.02 24.84 86.78 86.76 0.02 0.02 25.31 86.75 86.75 0.00 0.00 86.74 0.02 0.03
24.48 86.73 24.74 86.75 25.42 86.75
24.96 86.70 24.76 86.75 25.15 86.75
M. microti  14-58 ca t 28.43 86.67 86.71 0.03 0.04 28.04 86.77 86.77 0.01 0.01 28.91 86.75 86.77 0.02 0.02 86.75 0.04 0.04
28.38 86.73 28.55 86.78 28.36 86.78
28.48 86.72 28.53 86.77 29.15 86.77
M. microti  15-1955 ca t 24.62 86.73 86.75 0.02 0.02 24.81 86.77 86.76 0.01 0.01 25.08 86.80 86.78 0.02 0.02 86.76 0.02 0.02
24.08 86.77 24.45 86.77 24.69 86.77
23.90 86.75 24.62 86.75 24.87 86.77
M. microti  16-2156 ca t 26.87 86.75 86.77 0.03 0.03 27.19 86.70 86.71 0.02 0.02 27.80 86.75 86.75 0.00 0.00 86.74 0.03 0.04
27.08 86.77 27.08 86.70 27.42 86.75
26.65 86.80 27.16 86.73 27.39 86.75
M. microti 1522744 ca t 26.98 86.77 86.77 0.01 0.01 27.26 86.73 86.70 0.03 0.03 27.78 86.77 86.76 0.01 0.01 86.74 0.04 0.04
26.92 86.77 26.96 86.70 27.39 86.75
27.21 86.78 27.18 86.68 27.55 86.75
M. microti  16-1347 ca t 23.04 86.75 86.78 0.03 0.03 0.02 23.05 86.72 86.73 0.02 0.02 0.02 23.49 86.75 86.73 0.02 0.02 0.01 86.75 0.03 0.03 0.03
22.50 86.80 23.40 86.73 23.50 86.73
23.15 86.78 22.94 86.75 23.18 86.72
Run 1 Run 2 Run 3 Inter-Assa yIsolate
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Supplementary Table S2: Raw data set and statistical parameters generated from the intra- 
and inter-assay using a randomly chosen subset of 19 clinical specimens. 
 
 
 
 
 
 
 
MTBC member sample no ori gi n Ct Tm Mean Tm SD CV% Intra-assay CV% Ct Tm Mean Tm SD CV% Intra-assay CV% Ct Tm Mean Tm SD CV% Intra-assay CV% Mean Tm SD CV% Inter-assay CV%
M. microti ATCC 19422 23.07 86.52 22.75 86.70 22.68 86.48
M. bovis BCG Pas teur ATCC 35734 28.16 86.38 28.46 86.55 27.81 86.37
M. tuberculosis H37Rv 25.92 86.80 25.46 86.93 25.38 86.75
M. tuberculosis  15-961 2 el ephant 35.67 86.73 86.72 0.01 0.01 36.39 86.90 86.89 0.01 0.01 37.77 86.73 86.70 0.03 0.03 86.77 0.10 0.12
35.67 86.72 36.37 86.88 35.58 86.70
36.01 86.72 35.85 86.88 35.05 86.68
M. tuberculosis  15-961 1 el ephant 28.01 86.73 86.73 0.01 0.01 0.01 28.75 86.90 86.92 0.02 0.02 0.02 27.97 86.68 86.68 0.01 0.01 0.02 86.77 0.13 0.15 0.13
28.57 86.72 28.63 86.93 28.10 86.68
28.47 86.73 28.32 86.92 28.29 86.67
M. caprae  14-13 cow >40.00 86.25 86.24 0.01 0.01 >40.00 86.45 86.46 0.01 0.01 >40.00 86.45 86.41 0.04 0.04 86.37 0.11 0.13
>40.00 86.23 >40.00 86.45 >40.00 86.38
>40.00 86.25 >40.00 86.47 >40.00 86.40
M. caprae 22914 cow 33.14 86.43 86.41 0.02 0.02 33.14 86.60 86.57 0.03 0.03 32.18 86.35 86.34 0.02 0.02 86.44 0.12 0.13
33.15 86.40 33.00 86.55 33.34 86.35
33.49 86.40 33.64 86.55 32.35 86.32
M. caprae 22848 cow 21.81 86.38 86.39 0.01 0.01 21.55 86.57 86.55 0.03 0.03 21.23 86.35 86.34 0.01 0.01 86.43 0.11 0.12
21.9 86.40 21.52 86.52 21.36 86.35
21.89 86.38 21.78 86.55 21.59 86.33
M. caprae  13-162 cow >40.00 86.28 86.28 0.00 0.00 38.38 86.48 86.46 0.02 0.02 >40.00 86.37 86.38 0.02 0.02 86.37 0.09 0.10
38.43 86.28 38.53 86.45 39.77 86.40
39.58 86.28 39.61 86.45 >40.00 86.38
M. caprae 22971 cow 39.45 86.12 86.11 0.01 0.01 0.01 >40.00 86.30 86.32 0.03 0.03 0.02 >40.00 86.22 86.24 0.02 0.02 0.02 86.23 0.11 0.12 0.12
>40.00 86.10 >40.00 86.35 >40.00 86.25
>40.00 86.12 >40.00 86.32 >40.00 86.25
M. bovis 20593 cow 18.23 86.35 86.35 0.00 0.00 18.13 86.55 86.56 0.02 0.02 17.64 86.35 86.34 0.02 0.02 86.42 0.12 0.14
17.93 86.35 17.69 86.55 17.53 86.35
17.66 86.35 17.93 86.58 17.14 86.32
M. bovis 20594 cow 15.47 86.40 86.40 0.00 0.00 15.30 86.60 86.59 0.02 0.02 15.39 86.35 86.34 0.01 0.01 86.44 0.13 0.15
15.44 86.40 15.27 86.60 15.31 86.33
15.3 86.40 14.99 86.57 14.98 86.35
M. bovis 20609 cow 24.13 86.40 86.42 0.02 0.02 24.94 86.60 86.62 0.02 0.02 23.83 86.38 86.37 0.02 0.02 86.47 0.13 0.15
24.72 86.43 24.70 86.62 24.49 86.35
24.69 86.42 24.27 86.63 24.15 86.37
M. bovis 20606 cow 15.44 86.45 86.46 0.01 0.01 15.19 86.62 86.63 0.01 0.01 14.85 86.40 86.39 0.02 0.02 86.49 0.12 0.14
15.12 86.47 14.96 86.63 14.63 86.37
15.64 86.47 15.40 86.63 14.90 86.40
M. bovis 20596 cow 15.76 86.45 86.44 0.01 0.01 15.53 86.62 86.62 0.00 0.00 15.27 86.35 86.36 0.01 0.01 86.47 0.13 0.16
15.43 86.45 15.53 86.62 15.16 86.37
15.74 86.43 15.51 86.62 15.10 86.35
M. bovis 20600 cow 15.84 86.47 86.46 0.02 0.03 0.01 15.38 86.60 86.58 0.02 0.02 0.01 14.96 86.33 86.33 0.00 0.00 0.01 86.46 0.13 0.15 0.15
15.63 86.47 15.49 86.58 15.43 86.33
15.63 86.43 15.66 86.57 15.08 86.33
M. microti 22928 cat 24.51 86.60 86.57 0.03 0.03 24.33 86.72 86.70 0.02 0.02 23.78 86.43 86.45 0.03 0.03 86.58 0.12 0.14
24.29 86.57 24.37 86.70 24.19 86.48
24.52 86.55 24.46 86.68 24.02 86.45
M. microti  15-342 al paca 23.14 86.55 86.57 0.03 0.03 22.84 86.70 86.71 0.04 0.04 22.67 86.45 86.48 0.03 0.03 86.59 0.12 0.14
23.17 86.57 22.94 86.68 22.64 86.48
23.04 86.60 22.56 86.75 22.69 86.50
M. microti  17-1084 cat 26.85 86.57 86.56 0.01 0.01 27.01 86.68 86.70 0.03 0.03 26.48 86.50 86.51 0.01 0.01 86.59 0.10 0.12
26.64 86.55 26.85 86.70 26.64 86.50
26.92 86.57 26.74 86.73 26.59 86.52
M. microti  15-1955 cat 29.81 86.55 86.58 0.03 0.03 29.44 86.70 86.71 0.01 0.01 28.95 86.48 86.47 0.02 0.02 86.59 0.12 0.14
29.55 86.58 29.63 86.72 28.99 86.45
29.13 86.60 29.65 86.72 29.16 86.48
M. microti  14-690 al paca 22.76 86.60 86.58 0.03 0.03 22.86 86.75 86.74 0.01 0.01 22.82 86.50 86.52 0.02 0.02 86.61 0.12 0.14
23.18 86.58 22.95 86.75 22.57 86.52
23.02 86.55 22.96 86.73 22.50 86.53
M. microti  17-549 l l ama 32.87 86.58 86.60 0.02 0.02 0.03 33.75 86.77 86.75 0.03 0.03 0.02 33.28 86.52 86.49 0.03 0.03 0.02 86.61 0.13 0.15 0.14
33.28 86.62 33.44 86.75 32.55 86.47
33.62 86.60 33.52 86.72 32.48 86.48
Run 1 Run 2 Run 3 Inter-as s ayCl i nica l  s peci men
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Supplementary Figure S1: Real-time-PCR amplification curves and standard curves of the 
serial dilution using (a) M. tuberculosis H37Rv; (b) M. bovis BCG Pasteur ATCC 35734 and 
(c) M. microti ATCC 19422. 
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Supplementary Table S3:MTBC positive isolates used for the development of the high resolution melting assay. 
Sample Species Origin Specimen Culture? Clinical specimen? 
   M. bovis (15) 
20175 M. bovis cow lung cultured not available 
20482 M. bovis cow lung, lymph node pool cultured not available 
20531 M. bovis cow lymph node pool cultured not available 
20593 M. bovis cow lymph node pool cultured clinical specimen 
20594 M. bovis cow lymph node pool cultured clinical specimen 
20596 M. bovis cow lymph node pool cultured clinical specimen 
20597 M. bovis cow lymph node pool cultured not available 
20599 M. bovis cow lymph node pool cultured not available 
20600 M. bovis cow lymph node pool cultured clinical specimen 
20606 M. bovis cow lymph node pool cultured clinical specimen 
20608 M. bovis cow lymph node pool cultured clinical specimen 
20609 M. bovis cow lymph node pool cultured clinical specimen 
20665 M. bovis cow lymph node pool cultured not available 
22539 M. bovis cow lymph node cultured not available 
22667 M. bovis cow lymph node cultured not available 
   M. caprae (8) 
14-13  M. caprae Cow lymph node cultured clinical specimen 
22914 M. caprae Cow lymph node pool cultured clinical specimen 
22971 M. caprae Cow lymph node pool cultured clinical specimen 
22848 M. caprae Cow liver, lung, lymph node pool cultured clinical specimen 
22966 M. caprae Cow lymph node pool cultured not available 
13-450  M. caprae Cow lymph node cultured not available 
13-162 M. caprae Cow lymph node cultured not available 
20948 M. caprae Cow lymph node not available clinical specimen 
   M. microti (15) 
22928 M. microti cat lung, lymph node pool cultured clinical specimen 
15-1765  M. microti cat lung cultured clinical specimen 
15-342 M. microti alpaca lymph node cultured clinical specimen 
14-58 M. microti cat lung cultured clinical specimen 
14-690 M. microti alpaca liver cultured clinical specimen 
17-2287 M. microti alpaca spleen cultured clinical specimen 
15817 M. microti lama lymph node cultured clinical specimen 
15-1955 M. microti cat lymph node cultured clinical specimen 
16-2156 M. microti cat bronchoalveolar lavage cultured not available 
1522744 M. microti cat lung, lymph node pool cultured not available 
16-1347 M. microti cat lung cultured not available 
17-1084  M. microti cat lymph node, skin culture ongoing clinical specimen 
17-549 M. microti lama liver cultured clinical specimen 
17-1063 M. microti alpaca lymph node, lung, heart, liver, cervical 
vertebra culture ongoing clinical specimen 
MI16 M. microti wildboar (Spain) unknown cultured not available 
   M. tuberculosis (4) 
15-961-2  M. tuberculosis elephant 1 lung cultured clinical specimen 
15-961-1 M. tuberculosis elephant 1 pharyngeal swab not cultivated clinical specimen 
15-1115-2  M. tuberculosis elephant 2 lung cultured not available 
15-1221-1  M. tuberculosis elephant 3 lung cultured not available 
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Supplementary Table S4: An exclusivity panel consisting of 41 non-tuberculous 
mycobacteria and 3 non-mycobacterial species were tested for specificity of the high 
resolution melting assay. 
 
Species 
No. of 
isolates Species 
No. of 
isolates 
M. abscessus sp. 2 M. malmoense 1 
M. avium subsp. avium 2 M. marinum 1 
M. avium subsp. hominissuis 32 M. monacense 3 
M. avium subsp. paratuberculosis 1 M. nebraskense 1 
M. avium subsp. silvaticum 1 M. neoaurum 5 
M. bourgelatii 1 M. nonchromogenicum 7 
M. celatum 1 M. palustre 1 
M. chelonae subsp. chelonae 1 M. parafortuitum 2 
M. chimaera/intracellulare/youngonense 1 M. paragordonae 6 
M. chitae 1 M. peregrinum 2 
M. elephantis 1 M. persicum 2 
M. engbaekii 1 M. phlei 3 
M. europaeum 1 M. scrofulaceum 1 
M. fortuitum/porcinum 1 M. simiae 1 
M. goodii 1 M. smegmatis 1 
M. gordonae 2 M. szulgai 1 
M. hassiacum 1 M. terrae 1 
M. interjectum/paraense 1 M. vaccae 4 
M. intermedium 1 M. xenopi 5 
M. intracellulare 3 Nocardia paucivorans 1 
M. kansasii 10 Escherichia coli 1 
M. lymphaticum  1 Streptococcus suis 1 
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